Edgardo Baracchini has been appointed chief business officer of Imago Biosciences. His business development experience includes positions at Xencor (NASDAQ: [[ticker:XNCR]]), Metabasis Therapeutics, Elitra Pharmaceuticals, and Agouron Pharmaceuticals. San Francisco-based Imago develops treatments for bone marrow diseases. The company’s lead program, bomedemstat, is in mid-stage testing in myelofibrosis.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
